Eli Lilly and Company $LLY Shares Bought by Carr Financial Group Corp

Carr Financial Group Corp grew its holdings in Eli Lilly and Company (NYSE:LLY) by 19.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,999 shares of the company’s stock after buying an additional 655 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Carr Financial Group Corp’s investment portfolio, making the stock its 23rd largest position. Carr Financial Group Corp’s holdings in Eli Lilly and Company were worth $3,052,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Congress Park Capital LLC increased its holdings in Eli Lilly and Company by 11.6% in the 3rd quarter. Congress Park Capital LLC now owns 3,713 shares of the company’s stock worth $2,833,000 after acquiring an additional 386 shares in the last quarter. Silvia Mccoll Wealth Management LLC grew its position in shares of Eli Lilly and Company by 11.7% in the third quarter. Silvia Mccoll Wealth Management LLC now owns 496 shares of the company’s stock valued at $378,000 after purchasing an additional 52 shares during the period. Trinity Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the third quarter worth about $291,000. Cooper Financial Group increased its stake in shares of Eli Lilly and Company by 5.0% during the third quarter. Cooper Financial Group now owns 4,788 shares of the company’s stock worth $3,654,000 after purchasing an additional 229 shares in the last quarter. Finally, Montecito Bank & Trust acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth about $7,485,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on LLY shares. Leerink Partners reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday. UBS Group reaffirmed a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research report on Monday, December 1st. Cantor Fitzgerald restated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,141.73.

Eli Lilly and Company Stock Up 1.4%

Shares of LLY opened at $1,056.57 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock has a fifty day simple moving average of $956.00 and a two-hundred day simple moving average of $828.10. The company has a market capitalization of $998.86 billion, a PE ratio of 51.69, a price-to-earnings-growth ratio of 1.31 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.